Figure 4. Summary of recommendations on individual genotoxicity tests for NM FDA policy seems little changed, even concerning the requirement for accurate disclosure of the presence of NM. Most efforts to study NM ceased without notable differences in safety assessment approaches. Certainly, the shift to chemical characterization, in lieu of biological testing, obviates the collection of information about the effects of reduced size and physical effects of NM particles on biological systems.